54193-28-1 Usage
General Description
Adriamycinol is a derivative of the parent compound Adriamycin, which is also known as Doxorubicin. Adriamycinol is produced as a metabolic byproduct when Adriamycin is administered in cancer treatments. This chemical compound has proven effective in combating several types of cancer cells, including those involved in leukemia, breast cancer, and liver cancer. Adriamycinol's potency comes from its ability to interrupt the DNA replication process in cancer cells, causing them to die off. However, this compound can have serious side effects, including cardiotoxicity, hence the dosage must be carefully controlled.
Check Digit Verification of cas no
The CAS Registry Mumber 54193-28-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,1,9 and 3 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 54193-28:
(7*5)+(6*4)+(5*1)+(4*9)+(3*3)+(2*2)+(1*8)=121
121 % 10 = 1
So 54193-28-1 is a valid CAS Registry Number.
InChI:InChI=1/C27H31NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15-17,22,29-31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,16-,17-,22+,27-/m0/s1
54193-28-1Relevant articles and documents
Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism
Bains, Onkar S.,Karkling, Morgan J.,Lubieniecka, Joanna M.,Grigliatti, Thomas A.,Reid, Ronald E.,Riggs, K. Wayne
experimental part, p. 755 - 763 (2011/10/31)
Doxorubicin (DOX) and daunorubicin (DAUN) are anthracycline anticancer agents; however, considerable interpatient variability exists in their pharmacokinetics. This interpatient variability is attributed in part to altered metabolism by nonsynonymous sing
Anthracycline glycoside compositions, their use and preparation
-
, (2008/06/13)
Anthracycline glycoside antibiotics are complexed with cardiolipin and then encapsulated in liposomes to reduce mammalian cardiac tissue uptake of the anthracycline glycoside and to thereby reduce the deleterious effect of such cardiac tissue uptake. The invention is directed to the composition, preparation and use of the encapsulated complex of anthracycline glycoside.
